Omnes Capital's investments
AgomAb was founded through a collaboration between argenx and the University of Torino, Italy, based on the groundbreaking work of Paolo Michieli and his translational medicine team. The Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues and has produced a comprehensive preclinical package illustrating different applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases. Based in Ghent Belgium, it is backed by an International syndicate of experienced life sciences venture capital investors.
Teach on Mars
Teach on Mars is a 100% mobile-native learning technology provider. Our solution helps today’s organisations connect people with the learning and the communities they need to do their jobs and live their lives better. Winner of numerous industry awards, Teach on Mars is recognised as European leader in the mobile learning space. Since its foundation in 2013, the company has delivered its solution to over 100 blue-chip clients, in 20+ languages across more than 60 countries throughout the globe, and today it has bases in Sophia-Antipolis, Paris, Milan and London. 60 Teach on Mars staff and an extensive worldwide network of 40+ content and technology partners collaborate to equip organisations with the toolset, mindset and skillset required to create their next-generation learning ecosystem. And because Teach on Mars takes its responsibility for the future of our planet seriously, it invests 1% of its revenues in education projects contributing directly to the UNESCO Sustainsable Development Goals.
Thanks to a simple and fun service, "Geevers" can easily give and receive items for free in the proximity of their own homes. Available in Paris, Lyon, Marseille, Lille, Bordeaux, Nantes and Toulouse, GEEV has become an obvious alternative to selling, unnecessary storage and the proliferation of waste in the public space.
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. This second program has recently received up to $8.9 million funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Tilkee was founded by Sylvain Tillon and Timothée Saumet in decembre 2013. The company offers a complete suite of document tracking solutions: Tilkee for Sales, Tilkee for Marketing, Tilkee for Jobs and Tilkee for Events. Tilkee currently employs 24 people and is growing in Europe (Germany, United Kingdom, Spain). Tilkee’s clients include EDF, Orange, Schneider Electric, Credit Agricole and Adecco